None listed
Conditions
Brief summary
Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis or SAPHO syndrome, is a rare immuno-inflammatory bone disease that may be associated with skin changes. There are no clear guidelines for treatment. To assess the outcome of previously observed therapeutic treatments in SAPHO, we examined outcomes in 21 patients collected over more than 30 years of clinical experience. Mostly good or very good long-term treatment outcomes were observed in older bisphosphonate medications and newer biologic treatment called tumour necrosis factor inhibitor (TNFi) treatment.
Interventions
The clinical features and treatment outcomes in a cohort of 21 patients diagnosed with Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis or SAPHO syndrome, in Western Australia were reviewed retrospectively over a 32-year period by chart review and electronic medical record interrogation.
No involvement or consent was required. This was a retrospective data audit .
Sponsors
Graeme Carroll
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis of SAPHO as defined as multifocal osteitis with/without skin symptoms, sterile acute or chronic joint inflammation with either palmoplantar pustulosis or psoriasis, or acne or hidradenitis, with sterile osteitis with any one of these sets of criteria deemed sufficient for diagnosis.
Exclusion criteria
Those people that did not meet the criteria required to be diagnosed with SAPHO (multifocal osteitis with/without skin symptoms, sterile acute or chronic joint inflammation with either palmoplantar pustulosis or psoriasis, or acne or hidradenitis, with sterile osteitis with any one of these sets of criteria).
Outcome results
None listed